Introduction
Generate Biomedicines is a Somerville, Massachusetts clinical-stage biotechnology company founded in 2018 at Flagship Pioneering that applies generative biology — machine learning combined with high-throughput protein experimentation — to program novel protein therapeutics. Mike Nally serves as Chief Executive Officer per Generate’s investor leadership page reviewed in July 2026. Molly Gibson, PhD, co-founded the company alongside Avak Kahvejian, PhD, Geoffrey von Maltzahn, PhD, and Gevorg Grigoryan, PhD, following Flagship Labs explorations that merged complementary protein-design initiatives in 2019.
Generate describes its mission as leading a shift from traditional drug discovery toward drug generation — creating optimized biologics for historically difficult targets with unprecedented speed when its Generate Platform validates designs experimentally at scale.
What the company does
Generate Biomedicines integrates computational protein design with automated wet-lab testing to generate and optimize therapeutic candidates across modalities including antibodies, enzymes, and novel protein compositions. Its clinical pipeline includes GB-0895, a long-acting anti-TSLP antibody engineered with AI for severe asthma that Generate advanced toward global Phase 3 studies — a milestone Nally framed as demonstrating programmable biology’s ability to reach late-stage development within four years of engineering.
Partner collaborations include a September 2024 multi-target Novartis agreement leveraging the Generate Platform for protein therapeutics across disease areas, and an expanded January 2024 Amgen collaboration building on a 2022 initial partnership. Generate reported five clinical-stage molecules and multiple preclinical programs on its leadership page, supported by more than $750 million raised prior to its 2026 initial public offering referenced in investor materials.
The platform targets undruggable and hard-to-drug proteins by learning sequence-function relationships from large experimental datasets rather than relying solely on structural prediction alone.
Who it serves
Generate primarily advances internal pipeline programs while partnering with large pharmaceutical organizations through multi-target collaborations. Amgen and Novartis partnerships illustrate Generate’s dual model: owned clinical assets such as GB-0895 plus partner-funded discovery for targets where Generate’s generative platform accelerates candidate generation. Academic cancer center collaborations with MD Anderson and Roswell Park support oncology and CAR-T oriented programs referenced on Generate’s leadership page.
Company background
Flagship Pioneering launched Generate in 2018 after merging two Flagship Labs projects exploring machine learning for protein structure and generative biomedicine design. Gibson served as Chief Innovation Officer in early corporate materials; Kahvejian and von Maltzahn were initial co-CEO leaders before Nally’s appointment in 2021 brought enterprise scaling experience from Pfizer global vaccines leadership. Generate completed Series B and C financings — including the largest biotech Series C of 2023 per company communications — before its 2026 IPO raising approximately $400 million to advance platform and pipeline investments.
Somerville headquarters situates Generate in Greater Boston’s generative biology cluster alongside Flagship portfolio companies pursuing programmable medicine.
Product and AI capabilities
Generate’s AI learns from iterative design-build-test cycles at scale — each experimental result refining models that propose subsequent protein variants optimized for affinity, stability, and developability. GB-0895’s Phase 3 trajectory exemplifies this loop applied to a competitive immunology target (TSLP) where Generate claims a potentially best-in-class long-acting profile engineered intentionally through generative design rather than incremental human-led optimization alone.
Pharmaceutical partners evaluating Generate should assess target-specific validation data and commercial rights structures — platform capability does not substitute for indication-specific clinical outcomes.
Key developments
2018: Generate Biomedicines founded at Flagship Pioneering; Molly Gibson among co-founders. January 4, 2024: Amgen collaboration expansion and GB-0895 clinical progress highlighted at J.P. Morgan Healthcare Conference (media center). 2025–2026: GB-0895 global Phase 3 initiation announced (media center). Mike Nally CEO per investors.generatebiomedicines.com leadership page.
Why it matters
Generate Biomedicines matters because generative biology must prove clinical and commercial value beyond platform demonstrations — GB-0895 Phase 3 entry is Generate’s most visible test of whether AI-engineered biologics can compete on efficacy and developability with conventionally discovered drugs in large immunology markets. Nally’s leadership transition from pharmaceutical operations underscores Generate’s evolution from Flagship incubation to clinical-stage public biotech. Generate complements Brel coverage of AI drug discovery near Absci but emphasizes programmable protein generation across modalities rather than antibody-only de novo design.
Sector context
Generate Biomedicines belongs in Brel’s AI in healthcare coverage under biotechnology and generative AI drug creation. Readers should monitor Phase 3 enrollment and readout timelines separately from partnership announcement value — Novartis and Amgen deals validate platform interest but not individual asset approval.
Sources and references
Generate GB-0895 Phase 3 media center release and investor leadership team page.
- Generate — GB-0895 Phase 3 initiation (generatebiomedicines.com)
- Generate — Leadership team (investors.generatebiomedicines.com)
Reviewed July 10, 2026. Mike Nally is CEO; Molly Gibson is co-founder. Mikael Dolsten CSV error corrected.